Selected research
Industry Research
Etomidate Injection Industry Research Report 2026
Market perspective
The global Etomidate Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Etomidate Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Etomidate Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Etomidate Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Etomidate Injection include Mylan, Jiangsu Hengrui Medicine, Jiagnsu Nhwa Group, Pfizer, Zydus, Sagent, Par Sterile Products, Hikma and AuroMedics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Etomidate Injection market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Etomidate Injection Market by Company
Mylan
Jiangsu Hengrui Medicine
Jiagnsu Nhwa Group
Pfizer
Zydus
Sagent
Par Sterile Products
Hikma
AuroMedics
Athenex
American Regent
Etomidate Injection Segment by Type
20mg/10ml
40mg/20ml
Etomidate Injection Segment by Application
Clinics
Hospital
Recovery Center
Etomidate Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Etomidate Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Etomidate Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Etomidate Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Etomidate Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Etomidate Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Etomidate Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 20mg/10ml
- 40mg/20ml
Applications
- Clinics
- Hospital
- Recovery Center
Companies covered
- Mylan
- Jiangsu Hengrui Medicine
- Jiagnsu Nhwa Group
- Pfizer
- Zydus
- Sagent
- Par Sterile Products
- Hikma
- AuroMedics
- Athenex
- American Regent
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Etomidate Injection Market Size (2021-2032)
- 2.2.2 Global Etomidate Injection Sales (2021-2032)
- 2.2.3 Global Etomidate Injection Market Average Price (2021-2032)
- 2.3 Etomidate Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 20mg/10ml
- 2.3.3 40mg/20ml
- 2.4 Etomidate Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinics
- 2.4.3 Hospital
- 2.4.4 Recovery Center
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Etomidate Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Etomidate Injection Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Etomidate Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Etomidate Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Etomidate Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Etomidate Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Etomidate Injection, Product Type & Application
- 3.8 Global Manufacturers of Etomidate Injection, Established Date
- 3.9 Global Etomidate Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mylan
- 4.1.1 Mylan Company Information
- 4.1.2 Mylan Business Overview
- 4.1.3 Mylan Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mylan Etomidate Injection Product Portfolio
- 4.1.5 Mylan Recent Developments
- 4.2 Jiangsu Hengrui Medicine
- 4.2.1 Jiangsu Hengrui Medicine Company Information
- 4.2.2 Jiangsu Hengrui Medicine Business Overview
- 4.2.3 Jiangsu Hengrui Medicine Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Jiangsu Hengrui Medicine Etomidate Injection Product Portfolio
- 4.2.5 Jiangsu Hengrui Medicine Recent Developments
- 4.3 Jiagnsu Nhwa Group
- 4.3.1 Jiagnsu Nhwa Group Company Information
- 4.3.2 Jiagnsu Nhwa Group Business Overview
- 4.3.3 Jiagnsu Nhwa Group Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jiagnsu Nhwa Group Etomidate Injection Product Portfolio
- 4.3.5 Jiagnsu Nhwa Group Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Etomidate Injection Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Zydus
- 4.5.1 Zydus Company Information
- 4.5.2 Zydus Business Overview
- 4.5.3 Zydus Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zydus Etomidate Injection Product Portfolio
- 4.5.5 Zydus Recent Developments
- 4.6 Sagent
- 4.6.1 Sagent Company Information
- 4.6.2 Sagent Business Overview
- 4.6.3 Sagent Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sagent Etomidate Injection Product Portfolio
- 4.6.5 Sagent Recent Developments
- 4.7 Par Sterile Products
- 4.7.1 Par Sterile Products Company Information
- 4.7.2 Par Sterile Products Business Overview
- 4.7.3 Par Sterile Products Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Par Sterile Products Etomidate Injection Product Portfolio
- 4.7.5 Par Sterile Products Recent Developments
- 4.8 Hikma
- 4.8.1 Hikma Company Information
- 4.8.2 Hikma Business Overview
- 4.8.3 Hikma Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hikma Etomidate Injection Product Portfolio
- 4.8.5 Hikma Recent Developments
- 4.9 AuroMedics
- 4.9.1 AuroMedics Company Information
- 4.9.2 AuroMedics Business Overview
- 4.9.3 AuroMedics Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AuroMedics Etomidate Injection Product Portfolio
- 4.9.5 AuroMedics Recent Developments
- 4.10 Athenex
- 4.10.1 Athenex Company Information
- 4.10.2 Athenex Business Overview
- 4.10.3 Athenex Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Athenex Etomidate Injection Product Portfolio
- 4.10.5 Athenex Recent Developments
- 4.11 American Regent
- 4.11.1 American Regent Company Information
- 4.11.2 American Regent Business Overview
- 4.11.3 American Regent Etomidate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 American Regent Etomidate Injection Product Portfolio
- 4.11.5 American Regent Recent Developments
5 Global Etomidate Injection Market Scenario by Region
- 5.1 Global Etomidate Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Etomidate Injection Sales by Region: 2021-2032
- 5.2.1 Global Etomidate Injection Sales by Region: 2021-2026
- 5.2.2 Global Etomidate Injection Sales by Region: 2027-2032
- 5.3 Global Etomidate Injection Revenue by Region: 2021-2032
- 5.3.1 Global Etomidate Injection Revenue by Region: 2021-2026
- 5.3.2 Global Etomidate Injection Revenue by Region: 2027-2032
- 5.4 North America Etomidate Injection Market Facts & Figures by Country
- 5.4.1 North America Etomidate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Etomidate Injection Sales by Country (2021-2032)
- 5.4.3 North America Etomidate Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Etomidate Injection Market Facts & Figures by Country
- 5.5.1 Europe Etomidate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Etomidate Injection Sales by Country (2021-2032)
- 5.5.3 Europe Etomidate Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Etomidate Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Etomidate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Etomidate Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Etomidate Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Etomidate Injection Market Facts & Figures by Country
- 5.7.1 South America Etomidate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Etomidate Injection Sales by Country (2021-2032)
- 5.7.3 South America Etomidate Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Etomidate Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Etomidate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Etomidate Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Etomidate Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Etomidate Injection Sales by Type (2021-2032)
- 6.1.1 Global Etomidate Injection Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Etomidate Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Etomidate Injection Revenue by Type (2021-2032)
- 6.2.1 Global Etomidate Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Etomidate Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Etomidate Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Etomidate Injection Sales by Application (2021-2032)
- 7.1.1 Global Etomidate Injection Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Etomidate Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Etomidate Injection Revenue by Application (2021-2032)
- 7.2.1 Global Etomidate Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Etomidate Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Etomidate Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Etomidate Injection Value Chain Analysis
- 8.1.1 Etomidate Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Etomidate Injection Production Mode & Process
- 8.2 Etomidate Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Etomidate Injection Distributors
- 8.2.3 Etomidate Injection Customers
9 Global Etomidate Injection Analyzing Market Dynamics
- 9.1 Etomidate Injection Industry Trends
- 9.2 Etomidate Injection Industry Drivers
- 9.3 Etomidate Injection Industry Opportunities and Challenges
- 9.4 Etomidate Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst